José Luís
Zamorano Gómez
Catedrático/a de Universidad
José Ramón
González Juanatey
Publicaciones en las que colabora con José Ramón González Juanatey (29)
2023
-
Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study
European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360
-
Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
Patient Preference and Adherence, Vol. 17, pp. 839-849
2022
-
Challenges in managing patients with heart failure with reduced ejection fraction
Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 1-7
-
Role of vericiguat in the overall etiopathogenesis of heart failure with reduced ejection fraction. Current position
Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 8-14
-
Therapeutic approach to patients with heart failure with reduced ejection fraction. The role of vericiguat
Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 23-29
-
Vericiguat in heart failure: from scientific evidence to clinical practice
Revista Clinica Espanola
-
Vericiguat: VICTORIA trial results
Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 15-22
2021
-
A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure
Frontiers in Physiology, Vol. 12
-
Lipid lowering treatment in patients with very high risk cardiovascular disease. Spanish Society of Cardiology Consensus Document for the use of PCSK9 inhibitors in clinical practice
REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48
-
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433
-
Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de los iPCSK9 en la práctica clínica
REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48
2020
-
Prevalence, clinical profile and prognostic implications of interatrial block in patients admitted for heart failure
REC: CardioClinics, Vol. 55, Núm. 3, pp. 155-164
2019
2017
-
Cardiovascular efficacy and safety of bococizumab in high-risk patients
New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539
-
Evolocumab and clinical outcomes in patients with cardiovascular disease
New England Journal of Medicine, Vol. 376, Núm. 18, pp. 1713-1722
2016
-
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC
European Journal of Heart Failure, Vol. 18, Núm. 8, pp. 891-975
-
2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
Revista Espanola de Cardiologia, Vol. 69, Núm. 12, pp. 1167.-1167.
-
Comentarios a la guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
Revista Espanola de Cardiologia, Vol. 69, Núm. 12, pp. 1119-1125
-
Quality markers in cardiology: Measures of outcomes and clinical practice - A perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery
European Heart Journal, Vol. 37, Núm. 1, pp. 12-23
2015
-
2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management
Russian Journal of Cardiology, Vol. 124, Núm. 8, pp. 7-66